Abstract
The care of the febrile neutropenic patient has undergone a shift in the last 10 years with the realization that neutropenic patients presenting with fever do not constitute a homogeneous group. Strategies of risk assessment have allowed the testing of novel therapies including oupatient treatment with oral and intravenous antibiotics, either in combination regimens or as monotherapy; the addition of growth factors to hasten the return of the absolute neutrophil count; and the possibility of self-initiation of antibiotics by cancer patients when they develop fever. The clinical trials data regarding these new approaches will be reviewed, and areas requiring further research will be discussed.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sundararajan, V., Rubenstein, E., Rolston, K. et al. Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 5, 358–364 (1997). https://doi.org/10.1007/s005200050092
Published:
Issue Date:
DOI: https://doi.org/10.1007/s005200050092